TOP > 外国特許検索 > METHOD FOR PRODUCING MYOCARDIAL STEM CELL USED FOR TREATMENT AND/OR PREVENTION OF CARDIAC ARREST

METHOD FOR PRODUCING MYOCARDIAL STEM CELL USED FOR TREATMENT AND/OR PREVENTION OF CARDIAC ARREST

外国特許コード F180009468
整理番号 (S2017-0119-N0)
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP041250
国際公開番号 WO 2018092839
国際出願日 平成29年11月16日(2017.11.16)
国際公開日 平成30年5月24日(2018.5.24)
優先権データ
  • 特願2016-223069 (2016.11.16) JP
発明の名称 (英語) METHOD FOR PRODUCING MYOCARDIAL STEM CELL USED FOR TREATMENT AND/OR PREVENTION OF CARDIAC ARREST
発明の概要(英語) [Problem] To provide: a novel myocardial stem cell for transplantation that enables maintaining of a therapeutic effect on and/or preventative effect against cardiac arrest for a prolonged period; a method for producing said myocardial stem cell; and a cell preparation containing said myocardial stem cell.
[Solution] The present invention pertains to: a production method for a myocardial stem cell to be used for the treatment and/or prevention of cardiac arrest, the method comprising a step for introducing into a myocardial stem cell a complex of a mitochondria-targeted carrier and a mitochondria activating agent; a cell produced by said production method and a cell preparation containing same; and a liposome used to produce said cell. The present invention is able to provide a myocardial stem cell that is capable of maintaining a therapeutic effect by cell transplantation and/or a preventative effect thereby for a prolonged period.
従来技術、競合技術の概要(英語) BACKGROUND ART
Heart failure, myocardial infarction, angina or heart-related diseases such as cardiomyopathy, or hypertension, kidney disease or side effects of chemotherapy for malignant tumors such as due to non-cardiac disease, pulmonary or systemic deterioration of the function of the heart and the required amount of blood refers to a condition cannot be supplied. Heart failure, cancer in Japan is followed by a major killer, its fundamental therapy and heart transplantation. However, the heart transplant, chronic shortage of the transplant donor, limit the useful life of a transplanted organ, rejection, a lifelong immunosuppressant medicine, hospital to frequent catheter examination or the like, having a wide variety of problems.
2000 Promising therapy to the heart in the late cell transplantation since it has been proposed, including iPS cells using the cell transplantation therapy various cells have been studied. In particular, cardiac stem cell transplantation, implantation using self-cells for immunological safe, can be performed in a less invasive method has the advantage of such. Cardiac stem cell transplantation, clinical trials which demonstrated a certain effect (for example Non-Patent Document 1, Non-Patent Document 2, Non-Patent Document 3).
Cardiac stem cell transplantation problem is that, for example, myocardial ischemia reperfusion injury in the porcine model experiment stem cell transplant engraftment cells implanted in the limiting effect (Non-Patent Document 4), and the myocardial model rat doxorubicin cardiomyopathy stem cell transplant survival rate in the experiment to be limiting in effect (Non-Patent Document 5) and the like. That is, maintain the therapeutic effect of the long period of time, cardiac stem cell transplantation is one of the object in the future.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • HOKKAIDO UNIVERSITY
  • 発明者(英語)
  • HARASHIMA Hideyoshi
  • YAMADA Yuma
  • ABE Jiro
  • TAKEDA Atsuhito
国際特許分類(IPC)
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください

PAGE TOP

close
close
close
close
close
close